Drug Trial Radar · NCT01712984
Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
Last checked: Nov 19, 2026Latest source record: May 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,360
Actual
Start
Oct 2012
Primary completion
Jun 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 24, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of the study is to demonstrate safety and immunogenicity of the quadrivalent influenza intradermal (QIV-ID) vaccine compared to the trivalent influenza vaccine (TIV) containing the B strain from the primary (Yamagata) lineage (TIV-ID1) and the trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage (TIV-ID2) vaccines in producing protection against four strains of influenza virus. Primary Objective: * To demonstrate that QIV-ID induces an immune response (as assessed by hemagglutination inhibition (HAI) geometric mean titers (GMTs) and seroconversion rates) that is non-inferior to responses induced by TIV-ID1 and TIV-ID2 for the 4 virus strains at 28 days post-vaccination. Secondary Objectives: * To demonstrate that each B strain in QIV-ID induces an immune response (as assessed by HAI GMTs and seroconversion rates) that is superior to the response induced by the TIV-ID that does not contain the corresponding B strain. * To describe the rate of post-vaccination seroprotection induced by QIV-ID and TIV-ID. * To describe post-vaccination immunogenicity stratified by age (18-49 years and 50-64 years), race, ethnicity, gender, previous vaccination status, and baseline seropositivity status. * To describe the safety profile for subjects who receive QIV-ID and TIV-ID. Observational Objectives: * To demonstrate non-inferiority of QIV-ID compared to TIV-ID in terms of all Grade 2 or Grade 3 solicited systemic reactions combined * To demonstrate non-inferiority of QIV-ID compared to TIV-ID in terms of all Grade 3 solicited injection site reactions combined.
Conditions
- Influenza
Interventions
Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 FormulationBiological
0.1mL, Intradermal
Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® IntradermalBiological
0.1mL, Intradermal
Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone IntradermalBiological
0.1mL, Intradermal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Titers Against the Influenza Virus Antigens Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal RouteTime frame: Day 28 post-vaccination
- Number of Participants With Seroconversion to Influenza Virus Vaccine Antigens Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal RouteTime frame: Day 28 post-vaccination
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Hoover, Alabama
Site not named
Huntsville, Alabama
Site not named
Chandler, Arizona
Site not named
Mesa, Arizona
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Chula Vista, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Milford, Connecticut
Site not named
Coral Gables, Florida
Site not named
Melbourne, Florida
Site not named
Pinellas Park, Florida
Site not named
South Miami, Florida
Site not named
Boise, Idaho
Site not named
Iowa City, Iowa
Site not named
Overland Park, Kansas
Site not named
Wichita, Kansas
Site not named
Kansas City, Missouri
Site not named
Springfield, Missouri
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Binghamton, New York
Site not named
Rochester, New York
Site not named
Rochester, New York
Site not named
Allentown, Pennsylvania
Site not named
Bensalem, Pennsylvania
Site not named
Warwick, Rhode Island
Site not named
Mt. Pleasant, South Carolina
Site not named
Dakota Dunes, South Dakota
Site not named
Austin, Texas
Site not named
Fort Worth, Texas
Site not named
Fort Worth, Texas
Site not named
San Angelo, Texas
Site not named
Salt Lake City, Utah
Site not named
Salt Lake City, Utah
Site not named
West Jordan, Utah
Site not named
Marshfield, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.